1. Home
  2. WWR vs MCRB Comparison

WWR vs MCRB Comparison

Compare WWR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.62

Market Cap

82.3M

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$8.00

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
MCRB
Founded
1977
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.3M
85.7M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
WWR
MCRB
Price
$0.62
$8.00
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$1.92
$14.00
AVG Volume (30 Days)
993.0K
50.6K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$789,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$6.56
52 Week High
$3.75
$29.98

Technical Indicators

Market Signals
Indicator
WWR
MCRB
Relative Strength Index (RSI) 41.54 44.99
Support Level $0.58 $6.56
Resistance Level $0.72 $8.29
Average True Range (ATR) 0.03 0.57
MACD -0.00 0.07
Stochastic Oscillator 14.95 71.10

Price Performance

Historical Comparison
WWR
MCRB

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Share on Social Networks: